Company intelligence / Profile preview

SonoCiné

Reno, Nevada, United Statessonocine.com ↗

Ownership: Private
Development stage: Commercial

Overview

The addition of the SonoCiné AWBUS to standard mammography significantly increases the detection rate of small and otherwise occult breast cancers in women with dense breasts. Clinical studies have shown that combining this technology with mammography can double overall cancer detection rates and triple the detection of small tumors compared to mammography alone. The system has FDA 510(k) clearance as an adjunct screening tool and has been used in over 18,000 examinations worldwide.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy (Automated whole breast ultrasound imaging system)
Industry: Medical Imaging

Partnerships

None specifically disclosed; integration possible with any high-quality ultrasound machine manufacturers.

Beyond the preview

Go deeper on SonoCiné.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SonoCiné.

Explore the full profile